Abstract 96P
Background
Flot (5-fluorouracil, leucovorin, oxaliplatin and docetaxel) is the standard regimen for perioperative chemotherapy in locally advanced gastric cancer. Preoperative chemotherapy downstages the tumor, increases pathological response. Patients receiving flot are hospitalised for more than a day. This study compares it with dox (docetaxel, oxaliplatin and capecitabine) - a daycare regimen, as capecitabine has already been proven non-inferior to 5-fluorouracil in advanced gastric cancer.
Methods
62 patients were enrolled in this prospective observational study. 31 patients received 4 doses of 2 weekly infusions of 5-fluorouracil- 2600 mg/m2, leucovorin - 200 mg/m2, oxaliplatin - 85 mg/m2, docetaxel- 50 mg/m2 on day 1. Rest 31 received 3 doses of 3 weekly infusions of docetaxel- 60 mg/m2, oxaliplatin - 130 mg/m2 on day 1 and tablet capecitabine -1000 mg/m2 bid for 14 days. Radiological response to chemotherapy were analysed 2 weeks after chemotherapy completion and categorised into stable disease, partial response, progressive disease and complete response according to recist criteria version 1.1. Chi-square test was applied for analysis.
Results
In flot arm, 38.1 % (8) had partial response, 66.7 % (12) had progressive disease, 55 % (11) had stable disease radiologically. In dox arm, 61.9 %(13) had partial response, 33.3 % (6) had progressive disease, 45 % (9) had stable disease radiologically . 3 patients in dox regimen did not have evaluation (1 lost to follow-up; 2 died during the course of treatment). P value obtained was 0.197. The radiological response to chemotherapy was not statistically significant between two groups.
Conclusions
The radiological response to chemotherapy post flot or dox regimen is not statistically different. Dox maybe considered as an alternative regimen to flot in neoadjuvant chemotherapy in locally advanced gastric cancer patients with the advantage being a daycare procedure, requiring less resources and manpower.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
57P - V-set and immunoglobulin domain containing 1 (VSIG1): Gene vs protein expression in colorectal cancer tissue samples
Presenter: Simona Gurzu
Session: Poster viewing 02
58P - Clinicopathologic profile and outcomes of rectal cancer (RC) in the young (<50 years old): A single institution experience
Presenter: Fatma Amina Hussin Ibrahim
Session: Poster viewing 02
59P - Platelet-derived growth factor (PDGF)-CC serum as clinical outcome predictor after six cycles of chemotherapy in colorectal cancer at RSMH Palembang
Presenter: Erty Sundarita
Session: Poster viewing 02
60P - Predictors of survival in stage III colorectal cancer patients treated with surgery and adjuvant chemotherapy: A single institution observational study
Presenter: Keng Man Chiang
Session: Poster viewing 02
61P - Can total neoadjuvant therapy in locally advanced rectal cancer replace standard treatment protocol?
Presenter: Ankita Mallick
Session: Poster viewing 02
62P - Chief complaints and baseline clinicopathological features of patients with colorectal cancer in a tertiary hospital in Yogyakarta Indonesia
Presenter: Yasjudan Putra
Session: Poster viewing 02
63P - Tumor sidedness and clinicopathological features of colorectal cancer in Medical Oncology Department, Yangon General Hospital: A retrospective review
Presenter: Thiri Tun
Session: Poster viewing 02
64P - Clinical profile and treatment outcome of patients with non-metastatic colon cancer: A single institutional study from India
Presenter: Sandip Ganguly
Session: Poster viewing 02
65P - Comparison of survival and recurrence pattern in Thai early stage colorectal cancer patients by tumor sidedness
Presenter: Chanchai Charonpongsuntorn
Session: Poster viewing 02
77P - Long-term outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: The FUGES-012 randomized clinical trial
Presenter: Qing Zhong
Session: Poster viewing 02